BioAge Labs, Inc. (BIOA)
9.86
-0.25
(-2.47%)
USD |
NASDAQ |
Aug 26, 14:14
BioAge Labs Enterprise Value : 146.89M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 146.89M |
| August 24, 2026 | 113.48M |
| August 21, 2026 | 118.06M |
| August 20, 2026 | 127.67M |
| August 19, 2026 | 176.19M |
| August 18, 2026 | 162.92M |
| August 17, 2026 | 160.17M |
| August 14, 2026 | 169.33M |
| August 13, 2026 | 161.54M |
| August 12, 2026 | 163.83M |
| August 11, 2026 | 172.53M |
| August 10, 2026 | 208.24M |
| August 07, 2026 | 220.60M |
| August 06, 2026 | 200.00M |
| August 05, 2026 | 186.72M |
| August 04, 2026 | 196.79M |
| August 03, 2026 | 177.56M |
| July 31, 2026 | 97.91M |
| July 30, 2026 | 821.65M |
| July 29, 2026 | 699.88M |
| July 28, 2026 | 687.52M |
| July 27, 2026 | 639.91M |
| July 24, 2026 | 680.65M |
| July 23, 2026 | 686.60M |
| July 22, 2026 | 688.44M |
| Date | Value |
|---|---|
| July 21, 2026 | 720.94M |
| July 20, 2026 | 705.83M |
| July 17, 2026 | 728.26M |
| July 16, 2026 | 698.51M |
| July 15, 2026 | 723.23M |
| July 14, 2026 | 726.89M |
| July 13, 2026 | 681.34M |
| July 10, 2026 | 798.30M |
| July 09, 2026 | 823.48M |
| July 08, 2026 | 765.80M |
| July 07, 2026 | 801.05M |
| July 06, 2026 | 821.19M |
| July 02, 2026 | 833.09M |
| July 01, 2026 | 794.64M |
| June 30, 2026 | 806.08M |
| June 29, 2026 | 728.29M |
| June 26, 2026 | 675.47M |
| June 25, 2026 | 624.87M |
| June 24, 2026 | 634.19M |
| June 23, 2026 | 611.55M |
| June 22, 2026 | 573.82M |
| June 18, 2026 | 542.75M |
| June 17, 2026 | 508.13M |
| June 16, 2026 | 530.33M |
| June 15, 2026 | 501.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.207T |
| Pfizer Inc. | 214.62B |
| Oramed Pharmaceuticals, Inc. | 165.37M |
| Liquidia Corp. | 6.179B |
| Neumora Therapeutics, Inc. | 216.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.10M |
| Revenue (Quarterly) | 2.451M |
| Total Expenses (Quarterly) | 28.55M |
| EPS Diluted (Quarterly) | -0.582 |
| Gross Profit Margin (Quarterly) | 97.14% |
| Profit Margin (Quarterly) | -1.06K% |
| Earnings Yield | -24.21% |
| Normalized Earnings Yield | -24.11 |